Skip to content

The outlook for Chinese equities in 2026 is bright. Its ability to stand up to US trade demands reflects the narrowing technological gap between the two economies. We anticipate a less confrontational approach towards trade in 2026 as both sides seek to focus on growing their economies.

Market themes in 2026 include: rising corporate margins driven by anti-involution policies reducing unsustainable competition; increasing power demand as China’s Deepseek moment drives rising investment in data centers, and fiscal stimulus to support growth.

In the year ahead China will release its fifteenth five-year plan focusing on sustainable, efficient and balanced economic growth. We expect emphasis on consumption and innovation compared to investment and green energy in the 14th plan.

Sector beneficiaries in the Plan are expected to include semiconductors, consumer discretionary, power equipment and biotech. Prior plans were a useful roadmap for investors in deciding where to allocate capital.

Earnings and valuations

Consensus expectations for MSCI China 2026 earnings growth is 15%, with 35% forecast growth in the consumer discretionary sector,1 led by China’s internet and delivery platform giants. Anti-involution is expected to reduce unsustainable competition and boost corporate margins in the markets largest sector.

China Sector Earnings Growth 2026 Estimate

Sources: IBES, MSCI, as of 2 December 2025.

MSCI China 2026 price-to-earnings valuation of 12.6x is slightly above the long-term average,2reflecting the 28% gain in the index between January and mid December 2025. Global equity funds are 6.5% underweight China, compared to a post COVID-19 average of 5.5%.3This indicates there is potential for a pick-up in foreign fund inflows, given the prospects for a recovery in margins to drive earnings and still reasonable valuations.

Key themes

Anti-involution is a multi-year theme focusing on a pivot from price competition to quality driven growth. The policy is starting to drive rational competition with 2026 likely to bring about increased consolidation in sectors with over capacity. This is positive for corporate margins and return on equity, with large companies expected to be the biggest beneficiaries.

Deepseek moment. The release of Deepseek’s large language model in January 2025 shook the technology world. Its efficiency4 and use of open-source software gives it an edge in an environment where the needs of power hungry proprietary models are colliding with constrained power grids. China’s monthly token use in AI models is forecast to be in a range of 220-670Qa between from 2025 to 2030, compared to between 100-175Qa in the US.5 This is expected to require significant data center and in turn power investment.

Local governments in Gansu, Guizhou and Inner Mongolia have lowered power prices for data centers using domestically produced chips. This is a clear signal that China is prioritising growth of domestic AI models, with positive implications for power equipment suppliers.

China and US Hyperscaler Token Usage 2025 & 2030

Sources: Microsoft, Alphabet, Amazon. As of 1 December 2025.

Fiscal stimulus. The central government will increase bond issuance by CNY1Tn in 2026, with supply front loaded to the start of the year. The fiscal deficit is expected to increase to 4% of GDP. The stimulus will focus on boosting consumption and targeted support for innovation in sectors including semiconductors and those with high import content.

Sector views

China Sector Performance 2025

Sources: Bloomberg, MSCI, as of 2 December 2025.

Technology. China continues to close the technology gap with the US in the semiconductor sector. Technological independence remains a priority with the government committed to removing non Chinese software and replacing it with domestically developed solutions. Developing domestic ecosystems creates the potential for an alternative global AI supply chain. This may provide export opportunities to Belt and Road countries where China has already had success in exporting green technologies and electric vehicles.

Consumer discretionary. The impact of anti-involution is expected to be positive on the sector as companies pivot from competing solely on price to a focus on quality. We expect this to be positive for corporate margins as reflected in the 35% consensus earnings growth forecast for the sector. We remain positive on Chinese internet platform companies, viewing anti-involution as a positive catalyst.

Industrials. We are focused on the Chinese power equipment sector as the prime beneficiary in the growth in power demand for data centers and the replacement of ageing equipment globally. The IEA is forecasting the installed power base for data centers globally to increase by >20% annually between 2025–28. Given the capacity constraints in Europe and the US, Chinese power equipment companies have the potential to increase market share given their cost efficient, scalable solutions.

Health care. The Chinese biotech sector is witnessing significant growth, we are focused on oncology where China has witnessed a rise in its share of global trials to 39% in 2024 from 5% in 2014.6 The international acceptance of Chinese clinical data has increased investor confidence towards the sector. In particular its success in non-small cell lung cancer trials, which was validated in a study published in The Lancet medical journal in 2024.

China’s advantages in Biotech include:

  • Labour costs
  • Economies of scale
  • Supply chain
  • Government support
  • Cost effective R&D and patient trials.

The outlook for Chinese equities in 2026 is bright. Catalysts to drive the market higher include the positive effect of anti-involution on unsustainable competition. This has the potential to increase margins and drive consensus forecasts of 15% earnings growth. We are positive on the semiconductor, consumer discretionary, power equipment and biotech sectors.



Important Legal Information

This document is for information only and does not constitute investment advice or a recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. This document may not be reproduced, distributed or published without prior written permission from Franklin Templeton.

Any research and analysis contained in this document has been procured by Franklin Templeton for its own purposes and may be acted upon in that connection and, as such, is provided to you incidentally. Although information has been obtained from sources that Franklin Templeton believes to be reliable, no guarantee can be given as to its accuracy and such information may be incomplete or condensed and may be subject to change at any time without notice. Any views expressed are the views of the fund manager as of the date of this document and do not constitute investment advice. The underlying assumptions and these views are subject to change based on market and other conditions and may differ from other portfolio managers or of the firm as a whole. 

There is no assurance that any prediction, projection or forecast on the economy, stock market, bond market or the economic trends of the markets will be realized. Franklin Templeton accepts no liability whatsoever for any direct or indirect consequential loss arising from the use of any information, opinion or estimate herein.

The value of investments and the income from them can go down as well as up and you may not get back the full amount that you invested. Past performance is not necessarily indicative nor a guarantee of future performance.

Copyright© 2025 Franklin Templeton. All rights reserved. Issued by Templeton Asset Management Ltd. Registration Number (UEN) 199205211E.

CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.